Hims & Hers $HIMS ( ▲ 1.51% ) is still frequently viewed as a telehealth company selling treatments for hair loss, sexual health and, more recently, weight loss. But that description increasingly misses the bigger picture.

The company is building a broader consumer healthcare platform capable of launching new specialties through the same technology, brand, provider network, fulfillment infrastructure and customer acquisition engine. Each successful category potentially makes the next one easier to scale.

The latest quarter provided further evidence that this strategy is working. Growth accelerated, subscriber momentum improved and newer healthcare categories continued gaining traction even as the company invested heavily in its international expansion and broader product portfolio.

Weight loss remains important, but the long-term opportunity is becoming much larger than GLP-1s. The investment thesis ultimately comes down to whether Hims can become one of the dominant consumer healthcare platforms globally. The evidence increasingly suggests that it can. Let’s see why.